title: Cerium Oxide Nanoparticles Reduce Microglial Activation and Neurodegenerative Events in Light Damaged Retina.
abstract: The first target of any therapy for retinal neurodegeneration is to slow down the progression of the disease and to maintain visual function. Cerium oxide or ceria nanoparticles reduce oxidative stress, which is known to play a pivotal role in neurodegeneration. Our aim was to investigate whether cerium oxide nanoparticles were able to mitigate neurodegeneration including microglial activation and related inflammatory processes induced by exposure to high intensity light. Cerium oxide nanoparticles were injected intravitreally or intraveinously in albino Sprague-Dawley rats three weeks before exposing them to light damage of 1000 lux for 24 h. Electroretinographic recordings were performed a week after light damage. The progression of retinal degeneration was evaluated by measuring outer nuclear layer thickness and TUNEL staining to quantify photoreceptors death. Immunohistochemical analysis was used to evaluate retinal stress, neuroinflammatory cytokines and microglial activation. Only intravitreally injected ceria nanoparticles were detected at the level of photoreceptor outer segments 3 weeks after the light damage and electoretinographic recordings showed that ceria nanoparticles maintained visual response. Moreover, this treatment reduced neuronal death and "hot spot" extension preserving the outer nuclear layer morphology. It is noteworthy that in this work we demonstrated, for the first time, the ability of ceria nanoparticles to reduce microglial activation and their migration toward outer nuclear layer. All these evidences support ceria nanoparticles as a powerful therapeutic agent in retinal neurodegenerative processes.
authors.affiliation: Department of Applied Clinical Science and Biotechnology, University of L'Aquila, Via Vetoio, Coppito II, 67100 L'Aquila, Italy.
authors.forename: Lavinia
authors.initials: L
authors.lastname: Fiorani
authors.affiliation: Department of Physical and Chemical Sciences, University of L'Aquila, Via Vetoio, Coppito I, 67100 L'Aquila, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Passacantando
authors.affiliation: Department of Physical and Chemical Sciences, University of L'Aquila, Via Vetoio, Coppito I, 67100 L'Aquila, Italy.
authors.forename: Sandro
authors.initials: S
authors.lastname: Santucci
authors.affiliation: Department of Applied Clinical Science and Biotechnology, University of L'Aquila, Via Vetoio, Coppito II, 67100 L'Aquila, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Di Marco
authors.affiliation: Department of Applied Clinical Science and Biotechnology, University of L'Aquila, Via Vetoio, Coppito II, 67100 L'Aquila, Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Bisti
authors.affiliation: Department of Applied Clinical Science and Biotechnology, University of L'Aquila, Via Vetoio, Coppito II, 67100 L'Aquila, Italy.
authors.forename: Rita
authors.initials: R
authors.lastname: Maccarone
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis; D002563:Cerium / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007275:Injections, Intravenous; D058449:Intravitreal Injections; D008027:Light / Q000009:adverse effects; D017628:Microglia / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D018384:Oxidative Stress; D020419:Photoreceptor Cells, Vertebrate / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012162:Retinal Degeneration / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000975:Antioxidants; D002563:Cerium; C030583:ceric oxide